Navigation Links
Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
Date:5/6/2009

S. aureus; S. Lemaire, K. Kosowska-Shick, P. Appelbaum, F. Van Bambeke, P. Tulkens
  • P 1090: The safety of single ascending oral doses of TR-701, a novel oxazolidinone prodrug antibiotic; P. Bien, P. Prokocimer, KA. Munoz, J. Bohn
  • P 1089: The safety of multiple ascending oral doses of TR-701, a novel oxazolidinone prodrug antibiotic; P. Bien, P. Prokocimer, KA. Munoz, J. Bohn
  • P 1103: Characterization of resistance following serial passage of Staphylococcus aureus in the presence of the novel oxazolidinone TR-700 and linezolid; J. Locke, K. Shaw
  • P 1104: Characterization of the novel oxazolidinone TR-700 and linezolid spontaneous mutation frequencies and resistance mechanisms in Staphylococcus aureus; J. Locke, K. Shaw

  • Copies of these posters will be available on the Trius Web site following the ECCMID meeting: http://www.triusrx.com/posters.php.

    About Trius Therapeutics

    Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company's lead drug candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant Gram-positive bacterial pathogens including those resistant to Zyvox(R), the only marketed antibacterial drug of the oxazolidinone class. Trius has recently completed Phase 2 testing of torezolid in a U.S. based multi-center trial. Trius' pipeline includes two preclinical programs with lead candidates being developed to treat serious infections caused by Gram-negative bacterial pathogens. For more information, visit www.triusrx.co
    '/>"/>

    SOURCE Trius Therapeutics, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
    2. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
    3. Trius Doses First Patient in Antibacterial Phase 2 Trial
    4. PacificGMP Completes GMP Product Fill for Trius Therapeutics
    5. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
    6. Hyperion Therapeutics Receives Orphan Drug Designation for HPN-100 for the Treatment of Urea Cycle Disorders
    7. Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
    8. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
    9. Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders
    10. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
    11. Vantia Therapeutics Pipeline Continues to Mature
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/16/2014)... , Sept. 16, 2014  DNAtrix, Inc., experts ... first patient was treated with the company,s lead ... interferon in a randomized, multicenter, open-label Phase Ib ... "DNAtrix, in collaboration with leading neurosurgeons and neuro-oncologists ... initiation of our randomized Phase Ib study of ...
    (Date:9/16/2014)... NEW YORK , Sept. 16, 2014  Relmada ... therapies for the treatment of chronic pain, announced today ... Sloan Kettering Cancer Center (MSKCC) in a series of ... ER, a new tamper-resistant, extended release form of levorphanol. ... investigator for these studies. Dr. Pasternak ...
    (Date:9/16/2014)... 16, 2014  Eli Lilly and Company (NYSE: ... an agreement to co-develop and commercialize AZD3293, an ... in development as a potential treatment for Alzheimer,s ... is characterized by the accumulation of amyloid plaque ... with the development of beta-amyloid. Inhibiting BACE is ...
    Breaking Medicine Technology:DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 2Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 3Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 4
    ... for inherited conditions, ROCHESTER, Minn., Sept. 11 ... can be used to regenerate,heart tissue to treat ... was expedited by the editors of Stem Cells ... journal,s Web site at, http://stemcells.alphamedpress.org/ ., The ...
    ... PURCHASE, N.Y., Sept. 11 Nutrition 21, ... marketer of nutritional supplements under,the Iceland Health ... manage blood sugar levels, improve cardiovascular health, ... today that study results,released by the National ...
    Cached Medicine Technology:Stem Cell Regeneration Repairs Congenital Heart Defect 2Nutrition 21 Reports That National Toxicology Program Studies Support the Safety of Chromium Picolinate 2Nutrition 21 Reports That National Toxicology Program Studies Support the Safety of Chromium Picolinate 3Nutrition 21 Reports That National Toxicology Program Studies Support the Safety of Chromium Picolinate 4
    (Date:9/16/2014)... (PRWEB) September 16, 2014 SAMHSA, the federal ... mission a reduction of the impact of substance abuse and ... on the SAMHSA website in September is National Recovery Month, ... honor the gains made by those individuals in recovery. ... to addiction treatment in an effort to help those with ...
    (Date:9/16/2014)... REDWOOD CITY, CALIF. (PRWEB) September 16, 2014 ... contact center and customer service solutions, announced today ... Group Excellence in Learning Award for the creation ... for independent contractor agents. Brandon Hall Group honors ... strategies, modalities, processes, systems and tools that have ...
    (Date:9/16/2014)... Former Major League Baseball relief pitcher ... heart transplantation surgery at Allegheny General Hospital (AGH) on ... of his 16-year baseball career with the Pittsburgh Pirates ... Root Sports Pittsburgh, was discharged home on Friday, September ... surgical director of AGH’s heart transplant program. , “Mr. ...
    (Date:9/16/2014)... inoperable, early-stage lung cancer who receive stereotactic body ... of 40 percent, according to research presented today ... 56th Annual Meeting. Such a positive survival rate ... in poor tumor control for patients with inoperable ... RTOG 0236, originally published in 2010 , and ...
    (Date:9/16/2014)... to be on the heavy side. Researchers at the ... seven in every ten obese adults underestimate how much ... much less often. Mothers of overweight or obese children ... misjudge their obese mothers, size, says lead author Tracy ... in the Journal of General Internal Medicine , ...
    Breaking Medicine News(10 mins):Health News:Narconon Arrowhead Booklet Offers Tips During Recovery Month 2Health News:Narconon Arrowhead Booklet Offers Tips During Recovery Month 3Health News:LiveOps Wins Silver At The 2014 Brandon Hall Group Excellence In Learning Awards For Best Use Of Social/Collaborative Learning 2Health News:LiveOps Wins Silver At The 2014 Brandon Hall Group Excellence In Learning Awards For Best Use Of Social/Collaborative Learning 3Health News:LiveOps Wins Silver At The 2014 Brandon Hall Group Excellence In Learning Awards For Best Use Of Social/Collaborative Learning 4Health News:Former Pittsburgh Pirates Pitcher and Baseball Analyst Kent Tekulve Undergoes Successful Heart Transplant at Allegheny General Hospital 2Health News:Former Pittsburgh Pirates Pitcher and Baseball Analyst Kent Tekulve Undergoes Successful Heart Transplant at Allegheny General Hospital 3Health News:Long-term results of RTOG 0236 confirm good primary tumor control, positive 5-year survival rates 2Health News:Long-term results of RTOG 0236 confirm good primary tumor control, positive 5-year survival rates 3Health News:Poor body size judgement can lead to increased tolerance of obesity 2
    ... Your Medicines and You, Event Provides Free Pharmacist Reviews ... Mistakes, CHICAGO, Oct. 31 The following is ... one of the leading causes of death for,individuals over ... are teaming,up this Thursday to help people better manage ...
    ... Oct. 31 Varian, Inc.,(Nasdaq: VARI ) ... TOP-DNA and TOP-RNA, for the purification of,synthetic oligonucleotides ... used by life science researchers to,study the functions ... to work,properly, salts and incomplete products need to ...
    ... 11:01 AM October 31, 2007, WASHINGTON, ... of AARP told lawmakers what American families,already know ... our country is,the skyrocketing costs of health care., ... CEO Bill Novelli testified at a Senate Budget ...
    ... Another Scientific Review ... ... DENVER, Oct. 31 "The WCRF/AICR recommendations about,red meat and cancer are unsubstantiated ... red meat in a healthy,diet that far outweigh anything we,ve seen today. "There ...
    ... Open-Bore, Design to Bring High-Resolution MR Imaging to More Patients ... ... MALVERN, Pa., Oct. 31 Combining 3 Tesla strength and,sensitivity with a ... a 3 Tesla (T) MRI system with a 70 cm open bore ...
    ... to ways to treat injury, stroke and even Alzheimer,s, experts ... new U.S. study involving mice suggests the brain,s own stem ... injury. , These neural stem cells work by protecting existing ... team at the University of California, Irvine, were able to ...
    Cached Medicine News:Health News:Varian, Inc. Offers New Products for the Rapid Purification of Synthetic Oligonucleotides. 2Health News:AARP CEO Bill Novelli Tells Lawmakers: Controlling Health Care Costs Key to Budget Reform 2Health News:NCBA Statement on 2007 WCRF/AICR Second Expert Report on Food, Nutrition and Physical Activity and the Prevention of Cancer: 2Health News:3 Tesla + 70 cm + Tim = The Most Exciting Equation in MRI 2Health News:3 Tesla + 70 cm + Tim = The Most Exciting Equation in MRI 3Health News:3 Tesla + 70 cm + Tim = The Most Exciting Equation in MRI 4Health News:Stem Cells Restore Memory in Mice 2Health News:Stem Cells Restore Memory in Mice 3
    Adjustable piston accommodates 7-9mm trephine blade. Complete punch includes base plate, piston carrier, piston for 7 - 9mm trephine blades and 18mm diameter Teflon block. Designed for accurate donor...
    ... German Craftsmanship have produced ... in the world. Ocutek® ... to you! Only holders ... certificate, which requires and ...
    ... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
    ... Centuries of German Craftsmanship ... surgical instrumentation in the ... them available to you! ... coveted Meisterbrief certificate, which ...
    Medicine Products: